Probiotic strain of lactobacillus casei ferm bp-100059 (ferm p-19443) and its application, preparation of lactobacillus of probiotic action for humans, animals and plants, preventive or therapeutic agent against infection at humans, animals and plants
FIELD: medicine; biotechnologies.
SUBSTANCE: strain Lactobacillus casei FERM BP-100059 (FERM P-19443), possessing probiotic properties; grow up in the presence of any from one to four amino acids as a source of the nitrogen necessary for growth. At planting in suitable cultural to medium, the final value pH makes 4.0 or lower, and the highest acidity makes 1.5% or above. The strain resistable is to 5% salts of cholic acids. The strain produces an antibiotic. On the basis of the strain as the active beginning, the lactobacillus preparation of probiotic action for humans, animals and plants and the preventive or therapeutic agent against human, animal and plant infections.
EFFECT: ability to colonise and breed in the centres chronic the infections, steady against treatment, strong clearing action and destruction causing a bacterium infection.
12 cl, 5 dwg, 56 tbl, 34 ex
The text descriptions are given in facsimile form.
1. Lactobacillus casei FERM BP-programs 10059 (FERM P-19443), having the properties of the probiotic.
2. The strain according to claim 1, characterized in that it has the properties listed below in(1), (2), (3), (4) and (5):
(1) strain grown in the presence of any one to four amino acids as nitrogen source for growth;
(2) when providing a strong cultural environment inoculums equal number of cells of these strains and Escherichia coli and subjected to mixed cultivation under anaerobic conditions at 37°s With a finite number of cells of lactobacilli is 50% or more of the number of cells colibacteria;
(3) under cultivation in a suitable culture medium concnetrate pH is 4.0 or below;
(4) the strain is resistant to a 5%salts of bile acids;
(5) the strain produces substances with antimicrobial activity.
3. The strain according to claim 2, characterized in that
(a) is resistant to commonly used antibiotics;
(b) has the amylolytic power.
(c) stimulates the growth of Chlorella;
(d) grows in the temperature range from 5 to 45°C;
(e) grows in the pH range from pH 4.0 to pH 10,0;
(f) can grow well under any pressure of oxygen.
4. The preparation of lactobacilli probiotic action for humans, animals and plants, characterized in that it contains as active principle strain Lactobacillus casei FERM BP-programs 10059 (FERM P-19443).
5. The preparation according to claim 4, characterized in that the strain has properties according to any one of claim 2 or 3.
6. Prophylactic or therapeutic agent against infections in humans, animals and plants, characterized in that it contains as active principle strain Lactobacillus casei FERM BP - programs 10059 (FERMP-19443).
7. Preventive or therapeutic agent according to claim 6, characterized in that the strain has properties according to any one of claim 2 or 3.
8. Preventive or therapeutic agent according to claim 6, characterized in that it further comprises an antibiotic.
9. The use of Lactobacillus casei FERM BP - programs 10059 (FERM P-19443) as a Professor is completed or therapeutic agent for a person or animal in the treatment of periodontal diseases.
10. The use according to claim 9, wherein the prophylactic or therapeutic agent further comprises an antibiotic.
11. The use according to claim 9, wherein the prophylactic or therapeutic agent applied to the affected area after disinfection bactericidal disinfectant.
12. The application of claim 11, wherein the bactericidal disinfectant is bactericidal disinfectant, containing from 500 to 1500 ppm of iron ions, from 500 to 2000 ppm of L-ascorbic acid and from 200 to 2000 ppm of one or two compounds from a number of sorbic acid, benzoic acid and the complex ester peroxybenzoyl acid as main components.
FIELD: mining; biotechnology.
SUBSTANCE: bacteria strain Acidithiobacillus ferrooxidans "ИБ1" is extracted out of underspoil waste waters of Buribaisk ore dressing and processing enterprise. Rate of leaching is 0.057 g/(kg a day). Amount of copper extracted out of ore is 36%.
EFFECT: high rate of copper leaching out of waste sulphide ores.
3 tbl, 3 ex
FIELD: chemistry; biotechnology.
SUBSTANCE: method of culturing the strain Rhodococcus rhodochrous M33 provides the use of a culture medium, which is based on 12-60 mM phosphate buffer in demineralised water, which meets the cell requirements in phosphor. The value of the pH is kept in the interval from 5.5 to 9.0. After all the glucose provided has been used then acetic acid and/or its water soluble salt as the new source of carbon. The medium for cultivating the strain includes 7.9 g/l Na2HPO4x12H2O, 1.8 g/l KH2PO4, 0.02-0.04 g/l CoCl2x6H2O, 1.0 g/l MgSO4x7H2O, 0-10 g/l corn steep-water concentrate, 20-90 g/l glucose, 4-20 g/l urea, demineralised water. The medium is used in the following way. Nitrile hydrate activity is 7169 units/millilitre.
EFFECT: increased removal of biomass with high nitrilehydrase activity.
19 cl, 3 tbl, 7 ex
FIELD: medicine; pharmacology.
SUBSTANCE: substance for dermatological medical products on the basis of a collagenase of a microbic parentage represents an ultrafiltrate allocated from a cultural liquid of Streptomyces lavendulae strain VKPM S-910 with collagenolytic activity of 1800-2500 KEA/ml and proteolytic activity of 120-200 PE/ml.
EFFECT: obtaining of biologically active ultrafiltrate with high collagenolytic and proteolytic activity for an effective utilisation as a part of various wound-healthing preparations and dermatology.
FIELD: medicine, microbiology.
SUBSTANCE: invention concerns live vaccine recombinant strain Mycobacterium bovis-BCG, containing the nucleic acid, capable to express and coding, at least, one fiber or a polypeptide which shows alanine dehydrogenase activity, glutamine synthase activity or serine hydratase activity. The corresponding amino-acid and nucleotide sequences are resulted in the description. The recombinant strain can contain all nucleic acid either its part, or the nucleic acid containing sequence, at least on 60 % identical sequence of the specified nucleic acid. The strain can be used for preparation of a pharmaceutical composition, in particular, vaccines or immunogene composition for treatment or prevention of a mammal against infection with micobacteria. The strain under the invention survives is better and is longer persists in an organism of the owner, inducing long protective immunity.
EFFECT: provision of more effective vaccines for prevention of tuberculosis and other infections caused by micobacteria.
11 cl, 12 dwg, 2 tbl, 6 ex
FIELD: medicine, microbiology.
SUBSTANCE: invention concerns veterinary microbiology, in particular, cultivation of tuberculosis micobacteria on liquid nutrient mediums. Crops of culture of micobacteria carry out on a surface of the stab prepared from beef-extract agar, in addition containing on 100 of gel - 1.0-1.2 g of glucose and 2.0-2.2 ml of glycerine, height 8.0-8.2 cm and diameter 1.0-1.2 cm which acts over a surface of a liquid nutrient medium on 2-3 mm. For definition of diagnostic informativity of the given way of micobacteria cultivation, carry out seeding of reference strains of cultures of tuberculosis micobacteria: M.bovis (un. 8, IEV); M.tuberculosis (uit. H37Rv), M.avium (piece 780, IEV) M.smegmatis (cultures IEVSaFE). The invention allows to accelerate for 2-6 days primary and intensive growth of micobacteria of a tuberculosis in comparison with other ways of crops and promotes thus to the maximum accumulation of bacteriemic mass of cultures of micobacteria of a tuberculosis that testifies about its diagnostic informativity.
EFFECT: acceleration for 2-6 days of primary and intensive growth of tuberculosis micobacteria in comparison with other ways of crops and maintenance of the maximum accumulation of bacteriemic mass of cultures of tuberculosis micobacteria.
2 cl, 2 tbl, 6 ex
SUBSTANCE: said utility invention relates to the biotechnology and agriculture namely to the protection of plants against phytopathogenic fungi and bacteria. The strain Bacillus subtilis B-14 is isolated from soil and deposited in the Microorganism Culture Collection Research Institute of the State Centre for Virusology and Biotechnology VECTOR under the registration number B-1149. The strain demonstrates antagonistic properties against a broad spectrum of phytopathogenic fungi and bacteria, is undemanding as far as nutrient media are concerned, and may be used for the protection of various plant types against diseases.
EFFECT: obtaining a bacteria strain demonstrating antagonistic properties against a broad spectrum of phytopathogenic fungi and bacteria, and undemanding to nutrient media.
3 tbl, 5 ex
SUBSTANCE: invention relates to biotechnology. Strain of Alcaligenes denitrificans "ВКПМ В- 9582" - nitrilase producent and can be used in production of biocatalyst in process of carboxylic acids production.
EFFECT: increase of nitrilase output
1 tbl, 4 ex
FIELD: chemistry, milk production.
SUBSTANCE: strain of lactate bacteria Streptococcus thermophilus "ВКПМ В- 9587" is obtained from strain of S. thermophilus "ВС 104" in result of multi-step selection in conditions of higher temperature. Strain properties testify to expediency of its application in composition of poly-component ferment, as under unfavourable conditions - lowering of medium pH, temperature rise, as well as gradual depletion of nutritional medium composition in course of technological process, it is able to accomplish milk souring.
EFFECT: ensuring higher strain viability under unfavourable cultivation conditions.
3 tbl, 4 ex
FIELD: food products.
SUBSTANCE: starter for direct introduction into milk base contains in mixture or in the form of complex ("kit-of-part") at least one lactic-acid bacterium and at least one species of yeast lysate, content of yeast lysate in the starter accounts for 1 g of pure yeast lysate per 2×108 - 2×1013 lactic acid bacteria. Method of manufacturing fermented milk food products implies usage of the starter with the above composition provided that total amount of yeast lysate added to the milk base does not exceed 0.6 g of the pure yeast lysate per 1 l of the milk base.
EFFECT: ensuring maximum souring at the beginning of the fermentation and elimination of souring at the end stage.
26 cl, 3 dwg, 5 ex
SUBSTANCE: invention relates to biotechnology and can be used in medical and industrial microbiology. Trine medium contains fermentative beef hydrolysate, microbiological agar, sodium sulfite, triple-substituted sodium phosphate, sodium double-substituted sodium phosphate, sodium chloride and water from water-supply system in given ratio of ingredients.
EFFECT: obtaining pure culture of tuberculosis causative agent in shortest terms with further accelerated carrying out of differentiation and determining of antibiotic susceptibility.
FIELD: medicine; pharmacology.
SUBSTANCE: peroral pharmaceutical dosed out form for treatment of the conditions bound to secretion of acid in a stomach, includes an acid-sensible inhibitor of the proton pump and antagonist of H2-molecular switchers, with the delayed and-or prolonged liberation of the proton pump acid-sensible inhibitor, and fast liberation of antagonist of H2-molecular switchers.
EFFECT: maximum suppression of acid in a stomach after the first dose and throughout all course of treatment.
69 cl, 4 dwg, 7 ex
FIELD: medicine; veterinary science.
SUBSTANCE: vaccine includes inactivated adhesive antigens E.coli K88, E.coli K99, E.coli F-41, E.coli 987P and an adjuvant - aluminum hydrate. As the inactivated adhesive antigens E.coli use inactivated filamentous adhesive antigens E.coli K88 ab, E.coli K88 ad, E.coli K88 ad, E.coli K99, E.coli F-41, E.coli Att-25, E.coli 987P with activity level in reaction of the passive hemagglutination peer as 1:2048-4096; 1:1024-2048; 1:256-512; 1:1024-2056; 1:1024-2056; 1:32-64; 1:256-512, accordingly, at a following parity of components, wt. %: inactivated filamentous adhesive antigens E.coli K88 ab, E.coli K88 ad, E.coli K88 ad, E.coli K99, E.coli F-41, E.coli Att-25, E.coli 987P, taken in mass parities 1:(0.8-1.2:(0.8-1.2:(0.8-1.2:(0.8-1.2:(0.8-1.2:(0.8-1.2, accordingly - 55-65, 5.8-6.2%-s' aluminium hydrate the rest.
EFFECT: rising of safety of livestock of agricultural animals.
2 cl, 1 tbl, 8 ex
FIELD: medicine; pharmacology.
SUBSTANCE: perform processing of an elevated part and roots of the primrose plant (Primula macrocalyx Bge.) with an organic dissolvent - ligroin or hexane with the subsequent extraction with acetone and allocation of a target product using chromatography.
EFFECT: increase of output of the product.
4 ex, 2 dwg
FIELD: medicine; pharmacology.
SUBSTANCE: system of delivery of medicinal substance includes one department consisting from (i) of a kernel from thermoplastic polymer, filled with medicinal substance, (ii) an intermediate layer from the thermoplastic polymer filled with medicinal substance, and (iii) covers from the thermoplastic polymer, covering an intermediate layer and not containing medicinal substance, where the specified intermediate layer is filled (a) with crystals of the first pharmacologically active substance, and (b) the second pharmacologically active substance in the dissolved form and where the kernel is filled specified to the second pharmacologically active substance in the dissolved form. The delivery system is intended for vaginal introduction of the medicinal substance.
EFFECT: possibility of adjustment of rate of liberation of two or more active ingredients irrespective of others, at maintenance of long physical stability of system at room temperature.
51 cl, 21 dwg, 10 tbl, 4 ex
FIELD: chemistry, immonology.
SUBSTANCE: hybrid protein includes 936 protein sequence from Neisseria meningitides or protein with sequence identical to the mentioned protein sequence by 90% or more, and 741 protein sequence from Neisseria meningitides or protein with sequence identical to the mentioned protein sequence by 90% or more. The sequences can be linked by N- and/or C-end to histidine labels, with or without a linker. Linker is selected out of group of polyglycine linker, histidine labels and GSGGGG linker. A nucleic acid encoding this protein is displayed. Invention also claims composition for treatment and/or prevention of disease caused by Neisseria meningitides bacterium, based on hybrid protein and one or more proteins of the following group: 287, 741, ORF46.1, 961, NH2-A-[X-L-]n-B-COOH, where n=2, X1=287, and X2 is selected out group of: 953, 919, 961, 741. Invention claims application of composition in production of medicine for treatment of disease caused by Neisseria.
EFFECT: efficient treatment and prevention of disease.
13 cl, 5 dwg, 28 tbl, 1 ex
SUBSTANCE: invention concerns compounds of formula (I) and their pharmaceutically acceptable salts as β-lactamase inhibitors, method of their production, pharmaceutical composition based on them, and methods of treatment involving the claimed compounds. In the general formula (I) one of A and B is hydrogen, while the other is optionally substituted condensed bicyclic heteroaryl group; if aromatic ring part of bicyclic heteroaryl group is imidazole, non-aromatic ring part does not include S atom adjacent to head carbon atom of bridge group; X is S; R5 is H, C1-C6-alkyl or C5-C6-cycloalkyl; or its pharmaceutically acceptable salt where bicyclic heteroaryl group is (1-A) , where one of Z1, Z2 and Z3 is independently S, while the others are CR2 or S, if one of Z1-Z3 is carbon and is linked to the rest of molecule; W1, W2 and W3 are independently CR4R4, S, O or N-R1, if it does not form S-S, O-O, or S-O link with saturated ring system; t=1-4; R1 is H, C1-C6-alkyl, C5-C7-cycloalkyl, -C=O-aryl, -C=O(C1-C6)-alkyl, -C=O(C5-C6)-cycloalkyl, aryl-C1-C6-alkyl, optionally substituted C1-C6-alkoxy; heteroalkyl- C1-C6-alkyl or C=O(heteroaryl), where heteroaryl is 6-member ring containing 1 nitrogen atom, R2 is hydrogen, C1-C6-alkyl, R4 ir H, C1-C6-alkyl.
EFFECT: efficient application in bacterial infection treatment.
29 cl, 3 tbl, 58 ex
SUBSTANCE: invention relates to veterinary and medicine, particularly substances with cytostatic and bactericidal properties; it can be applied in pharmaceutical industry. The water-soluble composition includes, in wt %: 0.007 to 0.7 metronidazole, 0.0085 to 0.85 silver hexamethylenetetramine nitrate, 0.0284 to 2.84 sodium thiosulphate, water or physiological solution to 100.
EFFECT: obtaining of composition with cytostatic and bactericidal activity, lowered toxicity, and expanded storage time; it is inexpensive, can be prepared in the field, and moreover effective in therapy for leucosis in cattle
4 tbl, 6 ex
SUBSTANCE: invention relates to medicine, particularly to abdominal surgery, and applied to treatment for extensive peritonitis. To do it during operative intervention the peritonitis source is eliminated, and abdominal cavity sanation is performed. Then 3% methylcellulose gel, preliminary saturated with 1200 mg/l sodium hypochlorite solution in proportion 3:1, is introduced.
EFFECT: preventing of parietal and visceral peritoneum mesothelium injury by microbial exo- and endotoxins, anti-microbial effect prolongation of sodium hypochlorite, and preventing inactivation of sodium hypochlorite by peritoneal toxic effluent.
FIELD: medicine; pharmacology.
SUBSTANCE: essence of the invention includes selection of the damaged organs from the dead nutrias from the local epidemical centre from which prepare suspension, perform bacterial inoculation in differenrial diagnostic mediums, separate pure cultures of originators of colibacillosis, salmonellosis and enterococcus infections, separately grow up cultures Escherichia coli. Salmonella typhimurium and Streptococcus, fecalis in a meat infusion agar with addition of 0.2% of a glucose with titer 4-5 billion microbic cells in 1 cm3, inactivate by entering of formalin to 0.4-0.6 % final concentration, condition at temperature 37°C within 72-96 hours, admix cultures in equal parities, then bring a solution of a aluminium hydroxide in amount of 20% to the volume, carefully admix, pack up and cork.
EFFECT: increase of an adjuvanticity of a vaccine.
FIELD: medicine; pharmacology.
SUBSTANCE: agent possessing wound-healthing, antiinflammatory, antibacterial, immunomodulating, anaesthetising and antitumoral activity on a basis of terpenoids, contains a capsule extract of plants of Pinaceae bloodline exposed to short-term stressful influence, enriched with monoterpenes, obtained from a capsule extract. The pharmaceutical composition possessing wound-healthing, antiinflammatory, antibacterial, immunomodulating, anaesthetising and antitumoral activity, contains the above described agent in effective quantity and the target additive. Application of the above described agent for preparation of a medicinal preparation for treatment of pyoinflammatory diseases.
EFFECT: increased wound-healthing; antiinflammatory; antibacterial; immunomodulating; anaesthetising and antitumoral activities.
8 cl, 1 dwg, 6 tbl, 8 ex
SUBSTANCE: invention concerns medicine, namely to epidemiology, and concerns prophylaxes of nasopharingal carriage of a pathogenic microflora. For this purpose daily administer a Vitaflor probiotic intranasaly in a dose 2×108 CFU of lactic acid bacillus into 1 ml of dissolvent. Duration of administration - 3 weeks.
EFFECT: decrease of probability of respiratory diseases at expense of elimination of pathogenic originators and simultaneous stimulation of growth of own useful microflora.